Home › Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals, With $600M Commitment
 

Keywords :   


Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals, With $600M Commitment

2015-11-20 04:25:37| drugdiscoveryonline Home Page

Gurnet Point Capital, an investment firm focused on the healthcare and life sciences sectors that was founded by Ernesto Bertarelli and is led by Christopher A. Viehbacher, recently announced the creation of Boston Pharmaceuticals, a fully-integrated drug development company that will offer an innovative alternative model for drug development and commercialization.

Tags: company point development capital

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
04.11Tropical Depression Eighteen Graphics
04.11Tropical Depression Eighteen Public Advisory Number 4A
04.11Remnants of Patty Graphics
04.11Atlantic Tropical Weather Outlook
04.11Eastern North Pacific Tropical Weather Outlook
04.11Paper Excellence Group Rebrands as Domtar
04.11Registration Open for 2025 Waterborne Symposium
04.11ROSS Ribbon Blenders Provide Safe, Efficient Bulk Blending
More »